Inhibition of melanoma growth by subcutaneous administration of hTERTC27 viral cocktail in C57BL/6 mice

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-9

  Huo, Longfei ^a,f   Yao, Hong ^a,b   Wang, Xicai ^e   Wong, Gee Wan ^a,c   Kung, Hsiang Fu ^c   Lin, Marie C ^a,d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (China)

^e KUNMING MEDICAL UNIVERSITY   (China)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GANGLIOSIDE GM1 ANTIBODY; PARVOVIRUS VECTOR; TELOMERASE REVERSE TRANSCRIPTASE; CANCER VACCINE; TELOMERASE; TERT PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL ACTIVITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; FEMALE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LYMPHOCYTE SUBPOPULATION; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; SINGLE DRUG DOSE; SPLEEN CELL; T CELL DEPLETION; VIRAL GENE DELIVERY SYSTEM; VIRUS EXPRESSION; ADENO ASSOCIATED VIRUS; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; DISEASE MODEL; DOWN REGULATION; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; PATHOPHYSIOLOGY;

MUS; MUS MUSCULUS;

ADMINISTRATION, CUTANEOUS; ANIMALS; CANCER VACCINES; CELL PROLIFERATION; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; GENETIC VECTORS; HUMANS; KILLER CELLS, NATURAL; MELANOMA; MICE; MICE, INBRED C57BL; TELOMERASE;

EID: 77958583393     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012705     Document Type: Article

References (57)

1. Thompson JF, Scolyer RA, Kefford RF (2009) Cutaneous melanoma in the era of molecular profiling. Lancet 374: 362-365.
2. Pawlik TM, Sondak VK (2003) Malignant melanoma: current state of primary and adjuvant treatment. Crit Rev Oncol Hematol 45: 245-264.
3. Eggermont AM, Kirkwood JM (2004) Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 40: 1825-1836.
4. Brown CK, Kirkwood JM (2003) Medical management of melanoma. Surg Clin North Am 83: 283-322, viii.
5. Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, et al. (2001) Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J Clin Oncol 19: 3194-3202.
6. Huncharek M, Caubet JF, McGarry R (2001) Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 11: 75-81.
7. Tarhini AA, Agarwala SS (2006) Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 19: 19-25.
8. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351: 998-1012.
9. Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23: 488-496.
10. Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, et al. (2009) Immunotherapy of distant metastatic disease. Ann Oncol 20 Suppl 6: vi41-50.
11. Queirolo P, Acquati M (2005) Biochemotherapy in metastatic melanoma: quo vadis? Melanoma Res 15: 471-473.
12. Lens M, Ferrucci PF, Testori A (2008) Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings. Recent Pat Anticancer Drug Discov 3: 105-113.
13. Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, et al. (2009) Anti- CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 218: 69-70.
14. Fadel F, El Karoui K, Knebelmann B (2009) Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361: 211-212.
15. Blesa JMG, Pulido EG, Pulla MP, Candel VA (2009) Treatment options for metastatic melanoma-A systematic review. Cancer Therapy 7: 188-199.
16. Pilla L, Rivoltini L, Patuzzo R, Marrari A, Valdagni R, et al. (2009) Multipeptide vaccination in cancer patients. Expert Opin Biol Ther 9: 1043-1055.
17. Pilla L, Valenti R, Marrari A, Patuzzo R, Santinami M, et al. (2006) Vaccination: role in metastatic melanoma. Expert Rev Anticancer Ther 6: 1305-1318.
18. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915.
19. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, et al. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
20. Zimmermann S, Martens UM (2007) Telomeres and telomerase as targets for cancer therapy. Cell Mol Life Sci 64: 906-921.
21. Kim NW (1997) Clinical implications of telomerase in cancer. Eur J Cancer 33: 781-786.
22. Ramakrishnan S, Eppenberger U, Mueller H, Shinkai Y, Narayanan R (1998) Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res 58: 622-625.
23. Huo LF, Tang JW, Huang JJ, Huang PT, Huang CF, et al. (2006) Cancer immunotherapy targeting the telomerase reverse transcriptase. Cell Mol Immunol 3: 1-11.
24. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, et al. (2000) Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 97: 4796-4801.
25. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10: 673-679.
26. Huang JJ, Lin MC, Bai YX, Jing DD, Wong BC, et al. (2002) Ectopic expression of a COOH-terminal fragment of the human telomerase reverse transcriptase leads to telomere dysfunction and reduction of growth and tumorigenicity in HeLa cells. Cancer Res 62: 3226-3232.
27. Ng SS, Gao Y, Chau DH, Li GH, Lai LH, et al. (2007) A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide. Cancer Gene Ther 14: 561-572.
28. Ferrari FK, Samulski T, Shenk T, Samulski RJ (1996) Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 70: 3227-3234.
29. Chen Y, Luk KD, Cheung KM, Lu WW, An XM, et al. (2004) Combination of adeno-associated virus and adenovirus vectors expressing bone morphogenetic protein-2 produces enhanced osteogenic activity in immunocompetent rats. Biochem Biophys Res Commun 317: 675-681.
30. Gao Y, Ng SS, Chau DH, Yao H, Yang C, et al. (2008) Development of recombinant adeno-associated virus and adenovirus cocktail system for efficient hTERTC27 polypeptide-mediated cancer gene therapy. Cancer Gene Ther 15: 723-732.
31. Shay JW, Keith WN (2008) Targeting telomerase for cancer therapeutics. Br J Cancer 98: 677-683.
32. Waldhauer I, Steinle A (2008) NK cells and cancer immunosurveillance. Oncogene 27: 5932-5943.
33. Duthie MS, Kahn SJ (2006) During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single alphagalactosylceramide treatment. Immunology 119: 355-361.
34. Rottenberg M, Cardoni RL, Andersson R, Segura EL, Orn A (1988) Role of T helper/inducer cells as well as natural killer cells in resistance to Trypanosoma cruzi infection. Scand J Immunol 28: 573-582.
35. Ishikawa H, Hisaeda H, Taniguchi M, Nakayama T, Sakai T, et al. (2000) CD4(+) v(alpha)14 NKT cells play a crucial role in an early stage of protective immunity against infection with Leishmania major. Int Immunol 12: 1267-1274.
36. Sun R, Tian Z, Kulkarni S, Gao B (2004) IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners. J Immunol 172: 5648-5655.
37. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, et al. (2005) Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 201: 1973-1985.
38. Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, et al. (2002) HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168: 5900-5906.
39. Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, et al. (2001) Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 7: 3343-3348.
40. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, et al. (2000) Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6: 1011-1017.
41. Schroers R, Huang XF, Hammer J, Zhang J, Chen SY (2002) Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res 62: 2600-2605.
42. Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, et al. (2003) Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 9: 4743-4755.
43. Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, et al. (1999) Induction of immunity to antigens expressed by recombinant adenoassociated virus depends on the route of administration. Clin Immunol 92: 67-75.
44. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, et al. (2003) Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102: 964-971.
45. Linn YC, Hui KM (2003) Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma 44: 1457-1462.
46. Aggarwal S, Gurney AL (2002) IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 71: 1-8.
47. Kijima M, Saio M, Oyang GF, Suwa T, Miyauchi R, et al. (2005) Natural killer cells play a role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro. Int J Oncol 26: 679-684.
48. Misawa E, Sakurai T, Yamada M, Hayasawa H, Motoyoshi K (2003) Booster effect of interleukin-2 on natural killer 1.1+ cells stimulated by administration of macrophage colony-stimulating factor in mice. J Immunother 26: 21-30.
49. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T (2006) Antitumor activity of IFN-lambda in murine tumor models. J Immunol 176: 7686-7694.
50. Wang G, Tschoi M, Spolski R, Lou Y, Ozaki K, et al. (2003) In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 63: 9016-9022.
51. Yajima T, Nishimura H, Wajjwalku W, Harada M, Kuwano H, et al. (2002) Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int J Cancer 99: 573-578.
52. Clark PR, Stopeck AT, Parker SE, Hersh EM (2000) Cationic lipid gene transfer of an IL-2 transgene leads to activation of natural killer cells in a SCID mouse human tumor xenograft. Cell Immunol 204: 96-104.
53. Ortaldo JR, Winkler-Pickett RT, Bere EW, Jr., Watanabe M, Murphy WJ, et al. (2005) In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells. J Immunol 175: 693-699.
54. Talmadge JE, Phillips H, Schindler J, Tribble H, Pennington R (1987) Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res 47: 5725-5732.
55. Ye J, Ortaldo JR, Conlon K, Winkler-Pickett R, Young HA (1995) Cellular and molecular mechanisms of IFN-gamma production induced by IL-2 and IL-12 in a human NK cell line. J Leukoc Biol 58: 225-233.
56. Kurosawa S, Harada M, Matsuzaki G, Shinomiya Y, Terao H, et al. (1995) Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes. Immunology 85: 338-346.
57. Talmadge JE, Tribble HR, Pennington RW, Phillips H, Wiltrout RH (1987) Immunomodulatory and immunotherapeutic properties of recombinant gamma- interferon and recombinant tumor necrosis factor in mice. Cancer Res 47: 2563-2570